Home Cart Sign in  
Chemical Structure| 30299-08-2 Chemical Structure| 30299-08-2

Structure of Clinofibrate
CAS No.: 30299-08-2

Chemical Structure| 30299-08-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Clinofibrate is a HMG-CoA reductase inhibitor with IC50 value of 470 μM which can reduce plasma cholesterol levels and shows antihyperlipidemic effects.

Synonyms: S-8527

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Clinofibrate

CAS No. :30299-08-2
Formula : C28H36O6
M.W : 468.58
SMILES Code : CCC(OC1=CC=C(C2(C3=CC=C(OC(CC)(C)C(O)=O)C=C3)CCCCC2)C=C1)(C)C(O)=O
Synonyms :
S-8527
MDL No. :MFCD00865769
InChI Key :BMOVQUBVGICXQN-UHFFFAOYSA-N
Pubchem ID :2787

Safety of Clinofibrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.67mL

2.13mL

1.07mL

21.34mL

4.27mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Matsuura K, Hara A, et al. Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives. J Pharmacol Exp Ther. 1998 Jun;285(3):1096-103.

[2]Shirai K, Ishikawa Y, et al. Effect of clinofibrate on lipid metabolism of aorta in atherosclerotic rats. Artery. 1983;12(3):145-55.

[3]Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001 May 11;292(5519):1160-4. doi: 10.1126/science.1059344. PMID: 11349148.

[4]Matsuura K, Hara A, Kato M, Deyashiki Y, Miyabe Y, Ishikura S, Sugiyama T, Katagiri Y. Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives. J Pharmacol Exp Ther. 1998 Jun;285(3):1096-103. PMID: 9618412.

[5]Okazaki M, Zhang H, Ichino K, Amamiya M, Nakayama S, Oguchi K. Effects of clinofibrate on plasma fibrinogen level in high fructose diet-induced hyperlipidemic rats. In Vivo. 1994 Nov-Dec;8(6):1057-61. PMID: 7772737.

[6]Suzuki K. Effects of S-8527 (1,1-bis4'-(1"-carboxy'1"-methylpropoxy)-phenyl)-cyclohexane), a new hypolipidemic compound, on triglyceride metablolism in rats. Biochem Pharmacol. 1975 Jun 15;24(11-12):1203-7. doi: 10.1016/0006-2952(75)90063-5. PMID: 237511.

[7]Shirai K, Ishikawa Y, Nishide T, Sasaki N, Murano S, Matsuoka N, Saito Y, Yoshida S. Effect of clinofibrate on lipid metabolism of aorta in atherosclerotic rats. Artery. 1983;12(3):145-55. PMID: 6680996.

[8]Suzuki K, Aono S, Nakatani H. Hypolipidemic effect of a new aryloxy compound, S-8527, in experimental animals. Jpn J Pharmacol. 1974 Jun;24(3):407-14. doi: 10.1254/jjp.24.407. PMID: 4449146.

 

Historical Records

Categories